Lexington Biosciences, Inc. is a medical device company, which engages in the research and development of non-diagnostic devices. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2017-06-01. The device measures the function of the endothelium, the cells that line all arteries and are critical to the prevention of atherosclerosis, heart attacks and stroke. The firm is in the final stages of releasing the developed product for clinical studies. The firm's goal is to make HeartSentry accurate, quick, and cost effective so it can become the standard of care for cardiologists, general practitioners, and ultimately patients for first line evaluation of a person’s cardiovascular health.
Financials in millions USD. Fiscal year is February - January.
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Revenue
0
0
0
0
0
0
Revenue Growth (YoY)
--
--
--
--
--
--
Cost of Revenue
--
--
--
--
--
--
Gross Profit
--
--
--
--
--
--
Selling, General & Admin
0
0
0
0
0
0
Research & Development
--
--
--
--
0
0
Operating Expenses
0
0
0
0
0
0
Other Non Operating Income (Expenses)
--
--
--
--
--
--
Pretax Income
0
0
0
0
0
-1
Income Tax Expense
--
--
--
--
--
--
Net Income
0
0
0
0
0
-1
Net Income Growth
--
--
--
--
-100%
-50%
Shares Outstanding (Diluted)
27.45
27.45
27.45
27.45
12.05
3.78
Shares Change (YoY)
0%
0%
0%
128%
218%
0%
EPS (Diluted)
0
0
0
-0.01
-0.03
-0.33
EPS Growth
-22%
2%
-46%
-70%
-88%
-46%
Free Cash Flow
0
0
0
0
0
0
Free Cash Flow Per Share
--
--
--
--
--
--
Gross Margin
--
--
--
--
--
--
Operating Margin
0%
0%
0%
0%
0%
0%
Profit Margin
0%
0%
0%
0%
0%
0%
Free Cash Flow Margin
0%
0%
0%
0%
0%
0%
EBITDA
--
--
--
--
--
--
EBITDA Margin
--
--
--
--
--
--
D&A For EBITDA
--
--
--
--
--
--
EBIT
0
0
0
0
0
0
EBIT Margin
0%
0%
0%
0%
0%
0%
Effective Tax Rate
--
--
--
--
--
--
Follow-Up Questions
What are Lexington Biosciences Holdings Corp's key financial statements?
According to the latest financial statement (Form-10K), Lexington Biosciences Holdings Corp has a total asset of $0, Net loss of $0
What are the key financial ratios for LXGTF?
Lexington Biosciences Holdings Corp's Current ratio is 0, has a Net margin is 0, sales per share of $0.
How is Lexington Biosciences Holdings Corp's revenue broken down by segment or geography?
Lexington Biosciences Holdings Corp largest revenue segment is Marine Engine Related, at a revenue of 72,950,000,000 in the most earnings release.For geography, Japan is the primary market for Lexington Biosciences Holdings Corp, at a revenue of 40,986,000,000.
Is Lexington Biosciences Holdings Corp profitable?
no, according to the latest financial statements, Lexington Biosciences Holdings Corp has a net loss of $0
Does Lexington Biosciences Holdings Corp have any liabilities?
no, Lexington Biosciences Holdings Corp has liability of 0
How many outstanding shares for Lexington Biosciences Holdings Corp?
Lexington Biosciences Holdings Corp has a total outstanding shares of 0